BRAK LABS Peptide research, plainly written

what is the difference

GHK-Cu topical vs injected

The same copper-carrying tripeptide, sold two ways, sitting on opposite sides of the line between cosmetic law and drug law.

Last Reviewed Editorial policy Methodology

GHK-Cu is glycyl-L-histidyl-L-lysine holding a copper ion: three amino acids and a metal, a combination that occurs naturally in human blood plasma. Applied to skin under the ingredient name copper tripeptide-1, it is a listed cosmetic ingredient, which puts it inside a body of law written for cosmetics and makes an appearance claim about it lawful [7] [8].

Put in a vial and injected, the identical molecule is an unapproved drug. Nothing about the chemistry changes between the two products. What changes is the intended use the seller states, and United States law sorts an article into cosmetic or drug on that basis [8].

Not medical advice

This page reports what has been documented about a compound. It is not medical advice, not a diagnosis, not a dosing protocol, and not a recommendation to obtain or use anything described here. Talk to a licensed clinician about anything concerning your health. Read the full disclaimer.

Reviewed against editorial standards Updated

The short answer

The topical form is copper tripeptide-1, lawfully sold and lawfully advertised on how skin looks. The injected form has no approval of any kind and no published human study behind it.

The evidence gap between the routes is wider than the legal gap. On the topical side there are two independent randomised human trials, in 1992 and 2006, and neither separated from its control on an objective measure [1] [12]. GHK-Cu is graded B on its own review because that randomised evidence exists and has read out, which is what the letter records; the direction those trials went is carried in words beside it, because no grade on this site encodes direction. On the injected side, a 2026 review for orthopaedic and sports medicine physicians reports that no clinical data supports the use of GHK-Cu for musculoskeletal conditions [5], and a ClinicalTrials.gov query returned three registrations, only one of which is a trial of GHK-Cu itself, and none of them injected [6].

Side by side

GHK-Cu by route: what is the same, what differs, and where each fact comes from
PropertyTopical (copper tripeptide-1)Injected
Legal position in the United StatesA listed cosmetic ingredient under its INCI name. Lawful to sell, and lawful to advertise on how skin looks [7] [8]An unapproved drug. No approval and no monograph [8]
What the seller must doRegister the facility, list the product, hold safety substantiation records and report serious adverse events under the subchapter added by the Modernization of Cosmetics Regulation Act of 2022, with labelling at 21 CFR part 701. None of it requires evidence of effect [7] [8] [9]Nothing in that framework reaches an injectable presentation of an unapproved drug
Best independent human studyA randomised study after carbon dioxide laser resurfacing, 13 patients completing, with computer analysis and blinded evaluators. It found no significant difference between groups in redness, wrinkles or skin quality; only a validated patient questionnaire separated, at p equals 0.04 [1]None. This page found no published study giving the molecule by injection to a person for a systemic purpose [5]
Closest animal work to the routeNot applicable72 rats with a reconstructed anterior cruciate ligament, given GHK-Cu into the joint weekly for four weeks. A difference in knee laxity at six weeks did not remain at twelve [4]
Evidence grade on this siteGrade B. The scale measures how much research exists and how good it is, never which way it came out, so the direction is carried in words beside the letter on the review itself. One grade covers the compound, so it is the same letter on both sides of this tableGrade B, the same letter. A grade is derived for a compound, not for a route

Why the two get mixed up

There is nothing chemical to distinguish. Both products contain the same molecule, and a reader who checks finds the chemistry agreeing with the marketing: this really is one substance. The split is in what the seller says the product is for, and that is what the law reads.

The statute is explicit. A cosmetic is defined by an intention to cleanse, beautify, promote attractiveness or alter appearance; a drug by an intention to affect the structure or any function of the body, or to treat or prevent disease [8]. The same jar lands on either side depending on the sentences printed on it, so claim wording rather than formulation decides whether a copper peptide product is lawful.

The confusion then runs in a direction that matters. Because the topical form is lawful and has a genuine, if small, human literature, it gets read across to the injected form as though route were a delivery detail. A permeation result and a laser-resurfacing trial answer questions about skin, not about a molecule placed directly into a body. The same transfer happens with the mechanism writing: the paper most often cited in support of copper peptides is a 2008 review whose author's stated affiliation is a company selling copper peptide skin products rather than a university department [2], with a longer 2015 version from the same group [10].

What the published record covers for each

The independent human evidence here is topical, there is more of it than usually reported, and it went the wrong way for the product both times. The larger of the two came first: 86 evaluable patients with venous stasis ulcers, evaluator-blinded, where a tripeptide copper complex cream did not differ from an inert vehicle while silver sulfadiazine in the same trial beat both [12]. Patients underwent carbon dioxide laser resurfacing of the skin around the mouth and were randomised to a post-treatment regimen with or without the copper tripeptide complex, 13 completing. Computer analysis and blinded evaluators found no statistically significant difference between groups in redness, wrinkles or overall skin quality. The single measure that separated was a validated patient questionnaire, at p equals 0.04 [Human RCT] [1]. Thirteen patients is a small trial, and a small trial that finds nothing has not established that there is nothing to find.

That split is the most instructive result in the category. Instruments and blinded graders saw no difference; the people using the product reported one. Both answer different questions, and a page quoting either without the other is not reporting the study.

The physical question underneath any topical claim has been measured too. In a laboratory study using two skin models, almost no peptide and almost no copper crossed intact human skin, while microneedle pretreatment that punctured the barrier let measurable amounts of both through [In-vitro] [3]. A 2025 review of topically applied GHK sets out the same delivery problem alongside the mechanistic case for the molecule [11].

For the injected route there is no human record. A 2026 review for orthopaedic and sports medicine physicians surveyed the injectable peptides patients ask about and stated that no clinical data supports the use of GHK-Cu for musculoskeletal conditions [5]. A ClinicalTrials.gov query on 2 August 2026 returned three registrations under the compound and ingredient names, and not one is injected. Only one of the three is a trial of GHK-Cu itself: of the other two, one applied a multi-ingredient serum containing it to every participant with no control arm, and one measures circulating levels rather than giving anything [6].

The closest published work to an injected product is a rat study. Seventy-two animals had the anterior cruciate ligament reconstructed and were randomised to saline or one of two GHK-Cu concentrations, given into the joint weekly for four weeks. At six weeks the treated groups had a smaller side to side difference in knee laxity than saline. At twelve weeks, after administration stopped, no difference remained, and ultimate load, gait and histological scores did not separate [Animal] [4].

What this evidence can and cannot show. Those results come from rats with a surgically reconstructed ligament, not from people. An animal model is a deliberate simplification: the injury is created on purpose, the animal is young and healthy, and the outcome is measured at a fixed point rather than lived with. Mechanism is a reason to run a trial, not a substitute for one.

Our takeOne molecule, and the route decides both which law applies and whether anything has been measured. The topical side has two randomised trials that found nothing on any measure an assessor or an instrument made. The injected side has rats.

Frequently asked questions

Is topical GHK-Cu the same molecule as the injectable?

Yes, both are glycyl-L-histidyl-L-lysine bound to a copper ion. What differs is the legal position of each product and the evidence attached to each route, and neither transfers across.

Why is one lawful and the other not?

United States law sorts an article by intended use. A cosmetic is applied for cleansing, beautifying, promoting attractiveness or altering appearance; a drug is intended to affect the structure or any function of the body, or to treat or prevent disease [8]. Copper tripeptide-1 in a serum sold on how skin looks falls on the first side, and the same molecule in a vial sold for repair on the second.

Does MoCRA mean someone checked that a copper peptide serum works?

No. It added facility registration, product listing, safety substantiation records and serious adverse event reporting [7] [8] [9], and created no pre-market approval step for a cosmetic ingredient and no requirement to substantiate an efficacy claim to a regulator.

What has been published on injected GHK-Cu in people?

Nothing. A 2026 review for orthopaedic and sports medicine physicians states that no clinical data supports the use of GHK-Cu for musculoskeletal conditions [5], and a ClinicalTrials.gov query on 2 August 2026 returned three registrations, only one of which is a trial of GHK-Cu itself, and none of them injected [6].

If it barely crosses skin, is the injection the better route?

Not a question this page answers, and the permeation result does not bear on it either way. That study measured what crosses intact human skin in a laboratory cell, and found almost nothing until microneedles punctured the barrier [3]. An injection bypasses the barrier, so the finding says nothing about it, and no published human study of the injected route exists to put in its place.

References

  1. Miller TR, Wagner JD, Baack BR, Eisbach KJ. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg. 2006. PMID 16847171 DOI 10.1001/archfaci.8.4.252
  2. Pickart L. The human tri-peptide GHK and tissue remodeling. J Biomater Sci Polym Ed. 2008. PMID 18644225 DOI 10.1163/156856208784909435
  3. Li H, Low YS, Chong HP, Zin MT, Lee CY, Li B, Leolukman M, Kang L. Microneedle-Mediated Delivery of Copper Peptide Through Skin. Pharm Res. 2015. PMID 25690343 DOI 10.1007/s11095-015-1652-z
  4. Fu SC, Cheuk YC, Chiu WY, Yung SH, Rolf CG, Chan KM. Tripeptide-copper complex GHK-Cu (II) transiently improved healing outcome in a rat model of ACL reconstruction. J Orthop Res. 2015. PMID 25731775 DOI 10.1002/jor.22831
  5. Mayfield CK, Bolia IK, Feingold CL, Lin EH, Liu JN, Rick Hatch GF, Gamradt SC, Weber AE. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. Am J Sports Med. 2026. PMID 41476424 DOI 10.1177/03635465251357593
  6. US National Library of Medicine. ClinicalTrials.gov registry, queried through API v2 on 2 August 2026 for GHK-Cu and copper tripeptide. The query returned three registrations: NCT05932732, a completed facial skin quality study of a device-delivered treatment; NCT07706361, a not yet recruiting two-part study of a patch and circulating GHK and GHK-Cu levels in healthy adults; and NCT07437586, a recruiting phase 2 of topical GHK-Cu gel for acute skin wound healing. None tests an injected route. ClinicalTrials.gov. 2026. Source document
  7. United States Congress. Consolidated Appropriations Act, 2023, Public Law 117-328, enacted 29 December 2022. Division FF, title III, subtitle E is the Modernization of Cosmetics Regulation Act of 2022, which adds subchapter VI of the Federal Food, Drug, and Cosmetic Act. govinfo. 2022. Source document
  8. Office of the Law Revision Counsel, United States House of Representatives. Federal Food, Drug, and Cosmetic Act, title 21 of the United States Code: section 321 for the definitions of drug and cosmetic, and subchapter VI sections 364 to 364d for cosmetic definitions, adverse events, registration and product listing, and safety substantiation. Checked 2 August 2026. United States Code. 2026. Source document
  9. Office of the Federal Register and Government Publishing Office. Cosmetic labeling, title 21 of the Code of Federal Regulations, part 701. Checked 2 August 2026. Electronic Code of Federal Regulations. 2026. Source document
  10. Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int. 2015. PMID 26236730 DOI 10.1155/2015/648108
  11. Mortazavi SM, Mohammadi Vadoud SA, Moghimi HR. Topically applied GHK as an anti-wrinkle peptide: Advantages, problems and prospective. Bioimpacts. 2025. PMID 39963574 DOI 10.34172/bi.30071
  12. Bishop JB, Phillips LG, Mustoe TA, VanderZee AJ, Wiersema L, Roach DE, Heggers JP, Hill DP Jr, Taylor EL, Robson MC. A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers. J Vasc Surg. 1992. PMID 1495150 DOI 10.1067/mva.1992.37086